StockTipsArenaBeta

BUY Onesource Specialty Pharma Limited — Ashish Kyal, Waves Strategy Advisors

BUYOnesource Specialty Pharma Limited
Onesource Specialty Pharma share price target & all analyst calls

byAshish Kyal, Waves Strategy AdvisorsHorizon: NA (inferred Swing (≤2wk))6 Nov 2026via CNBC Awaaz.

Entry₹1,612.85Inferred
Target₹1,770
Total upside +9.74%
Stop loss₹1,565-2.97% risk
CMP₹1,599.81d ago
Active-0.81%+10.64%upside left 13d left
Follow Ashish Kyal for new calls(28% target hit, 173 closed calls)Get alertsWatch ONESOURCE for new buy/sell callsGet alertsSee 2 other Swing calls on ONESOURCESee 203 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:23 pm IST
10 supporting2 neutral2 opposing
Supports the BUY call (10)

MACD above its signal line — bullish momentum

Technicals · macd·7 Nov · today

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·6 Nov · yesterday

OneSource Receives USFDA EIR With VAI Status For Bengaluru Sterile Unit

NewsGoogle News·30 Oct · 1w ago

(opens in new tab)

OneSource Specialty Pharma gets USFDA VAI for Bengaluru sterile facility

NewsGoogle News·30 Oct · 1w ago

(opens in new tab)

OneSource Specialty Pharma USFDA EIR VAI Bengaluru SPD

NewsGoogle News·30 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (2)

OneSource targets 225-230 sterile days for second DDC line

NewsGoogle News·4 Nov · 3d ago

(opens in new tab)

OneSource retains $400 million FY28 target despite Line 3 delay

NewsGoogle News·4 Nov · 3d ago

(opens in new tab)
Weighs against the BUY call (2)

RSI at 71 — overbought territory

Technicals · rsi·7 Nov · today

OneSource injectable shutdown lasts through Q3, lines in January

NewsGoogle News·4 Nov · 3d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Onesource Specialty Pharma

All analyst calls on Onesource Specialty Pharma

More from Ashish Kyal, Waves Strategy Advisors

Every call and its outcome